Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study

S. Zweijpfenning (Nijmegen, Netherlands), S. Kops (Nijmegen, Netherlands), M. Boeree (Nijmegen, Netherlands), S. Kuipers (Nijmegen, Netherlands), J. Van Ingen (Nijmegen, Netherlands), W. Hoefsloot (Nijmegen, Netherlands), C. Magis-Escurra (Nijmegen, Netherlands)

Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Session: Tuberculosis and non-TB mycobacterial infection I
Session type: Oral Presentation
Number: 3821
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Zweijpfenning (Nijmegen, Netherlands), S. Kops (Nijmegen, Netherlands), M. Boeree (Nijmegen, Netherlands), S. Kuipers (Nijmegen, Netherlands), J. Van Ingen (Nijmegen, Netherlands), W. Hoefsloot (Nijmegen, Netherlands), C. Magis-Escurra (Nijmegen, Netherlands). Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study. 3821

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease
Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019
Year: 2020



A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease
Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis
Year: 2006


Effect of clarithromycin alone and clarithromycin containing regimen for mycobacteriun avium complex pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 558s
Year: 2006

Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment
Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections
Year: 2009


Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease
Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection
Year: 2019


Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013

A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

The clinical effect of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease - including a long-term follow-up study
Source: Eur Respir J 2004; 24: Suppl. 48, 721s
Year: 2004

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease
Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019
Year: 2019



Treatment outcome of combination antibiotic therapy including clarithromycin for Mycobacterium avium complex pulmonary disease
Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis
Year: 2010

The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 546s
Year: 2002

The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study
Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019
Year: 2020



A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis
Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis
Year: 2007


Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease
Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Year: 2018



A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015

Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019

Treatment results of cases of severe pulmonary tuberculosis with using rifabutin
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001

Efficacy and safety of kanamycin addition in patients with drug-refractory mycobacterium avium complex lung disease
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015


Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 40s
Year: 2003

Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011